Collegium (COLL) Q1 2026 Earnings Transcript

Collegium Pharmaceutical reported Q1 total net product revenue of $193.5 million, up 9% year over year, with JORNAY revenue rising 36% to $38.9 million and adjusted EBITDA increasing 9% to $103.9 million. The company reiterated 2026 guidance of $805 million to $825 million in product revenue and $455 million to $475 million in adjusted EBITDA, while announcing a $650 million cash acquisition of AZSTARYS plus up to $135 million in milestones. Management expects AZSTARYS to add more than $50 million of second-half 2026 net revenue and over $50 million of cost synergies within 12 months, alongside $150 million remaining in share repurchase authorization.

Analysis

The setup is no longer a single-product story; it is a cash-generating ADHD platform being re-rated as a multi-brand franchise. The most important second-order effect is portfolio compression of commercial risk: by stacking two differentiated stimulants against the same prescriber base, the company can raise share-of-voice without linearly expanding the field force, which should improve incremental ROI and make earnings less dependent on any one SKU. That matters because the market tends to underwrite branded ADHD assets as launch-and-defend businesses; here, the operating leverage can come from routing the same rep call through two distinct patient profiles.

The AZSTARYS deal is interesting less for headline accretion than for what it does to duration. The acquisition effectively converts near-term ADHD momentum into a longer visible runway by extending IP and creating a more diversified revenue bridge into the late 2030s, while the balance sheet remains serviceable at around 2x leverage post-close. The hidden risk is integration complexity: if management overestimates cross-sell efficiency or overpays for synergy capture, the market could quickly shift from valuing durability to questioning payback on the acquisition multiple, especially if payer access forces higher gross-to-net spending to defend both brands.

Pain is the quiet underpinning of the equity case and the part most likely to be misread. The authorized-generic structure should soften cliff risk by turning what would have been pure erosion into a revenue-sharing stream, but it also changes the business mix toward lower-growth, more cash-yielding economics that may cap multiple expansion if ADHD execution stumbles. Near term, the likely catalyst sequence is: close AZSTARYS, update guidance, then re-rate on evidence that the combined sales force can sustain high-single-digit revenue growth without a disproportionate expense step-up.

Contrarian view: the stock may still be underappreciated if investors are anchoring on opioid legacy risk and missing that the cash engine is funding a second growth leg with long patent coverage. The flip side is that consensus may be overestimating how much of JORNAY/AZSTARYS growth is truly additive versus share-shift within a limited stimulant market; if prescription growth slows, the incremental value of the deal compresses quickly.

Key Decisions for Investors

• Long COLL for 3-6 months into AZSTARYS close and updated combined guidance; the thesis is multiple expansion on de-risked growth duration, with downside if integration commentary turns vague or synergy targets slip.
• Sell COLL Jan-2027 out-of-the-money calls against a long equity position to monetize the likely volatility crush after the acquisition closes and guidance is reset.
• Pair trade: long COLL / short a slower-growth specialty pharma cash cow over 6-12 months; COLl should outperform if the market rewards durable top-line growth plus buybacks, but the short should be sized tightly because leverage is still moderate.
• If the stock rallies sharply pre-close, consider trimming 25-30% and re-entering on post-close digestion; the market often re-tests synergy assumptions after the first combined quarter.
• Watch for a relative-value long versus any name exposed to pure stimulant commoditization; if the ADHD market remains competitive, COLL’s multi-brand structure should outperform single-asset peers over the next 2-4 quarters.